Abstract
β-Arrestins 1 and 2 are multifunctional adaptor proteins originally discovered for their role in desensitizing seven-transmembrane receptor signaling via the heterotrimeric guanine nucleotide-binding proteins. Recently identified roles of β-arrestins include regulation of cancer cell chemotaxis and proliferation. Herein, we report that β-arrestin1 expression regulates breast tumor colonization in nude mice and cancer cell viability during hypoxia. β-Arrestin1 robustly interacts with nuclear hypoxia-induced factor-1α (HIF-1α) that is stabilized during hypoxia and potentiates HIF-1-dependent transcription of the angiogenic factor vascular endothelial growth factor-A (VEGF-A). Increased expression of β-arrestin1 in human breast cancer (infiltrating ductal carcinoma or IDC and metastatic IDC) correlates with increased levels of VEGF-A. While the anti-angiogenic drug thalidomide inhibits HIF-1-dependent VEGF transcription in breast carcinoma cells, it does not prevent HIF-1α stabilization, but leads to aberrant localization of HIF-1α to the perinuclear compartments and surprisingly stimulates nuclear export of β-arrestin1. Additionally, imatinib mesylate that inhibits release of VEGF induces nuclear export of β-arrestin1–HIF-1α complexes. Our findings suggest that β-arrestin1 regulates nuclear signaling during hypoxia to promote survival of breast cancer cells via VEGF signaling and that drugs that induce its translocation from the nucleus to the cytoplasm could be useful in anti-angiogenic and breast cancer therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alvarez CJ, Lodeiro M, Theodoropoulou M, Camina JP, Casanueva FF, Pazos Y . (2009). Obestatin stimulates Akt signalling in gastric cancer cells through beta-arrestin-mediated epidermal growth factor receptor transactivation. Endocr Relat Cancer 16: 599–611.
Arany Z, Huang LE, Eckner R, Bhattacharya S, Jiang C, Goldberg MA et al. (1996). An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93: 12969–12973.
Attramadal H, Arriza JL, Aoki C, Dawson TM, Codina J, Kwatra MM et al. (1992). Beta-arrestin2, a novel member of the arrestin/beta-arrestin gene family. J Biol Chem 267: 17882–17890.
Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ . (2004). Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96: 46–55.
Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN . (2006). Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 103: 1492–1497.
Chuaqui RF, Zhuang Z, Emmert-Buck MR, Liotta LA, Merino MJ . (1997). Analysis of loss of heterozygosity on chromosome 11q13 in atypical ductal hyperplasia and in situ carcinoma of the breast. Am J Pathol 150: 297–303.
D'Amato RJ, Loughnan MS, Flynn E, Folkman J . (1994). Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082–4085.
Daaka Y . (2004). G proteins in cancer: the prostate cancer paradigm. Sci STKE 2004: re2.
Dasgupta P, Rastogi S, Pillai S, Ordonez-Ercan D, Morris M, Haura E et al. (2006). Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways. J Clin Invest 116: 2208–2217.
DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK . (2007). Beta-arrestins and cell signaling. Annu Rev Physiol 69: 483–510.
Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW et al. (2002). Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 87: 1166–1172.
Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E et al. (2002). Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol Cancer Res 1: 89–95.
Ferrara N, Gerber HP, LeCouter J . (2003). The biology of VEGF and its receptors. Nat Med 9: 669–676.
Figg WD . (2006). The 2005 Leon I. Goldberg Young Investigator Award Lecture: development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer. Clin Pharmacol Ther 79: 1–8.
Folkman J, Merler E, Abernathy C, Williams G . (1971). Isolation of a tumor factor responsible for angiogenesis. J Exp Med 133: 275–288.
Gavard J, Gutkind JS . (2006). VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 8: 1223–1234.
Ge L, Shenoy SK, Lefkowitz RJ, DeFea K . (2004). Constitutive protease-activated receptor-2-mediated migration of MDA MB-231 breast cancer cells requires both beta-arrestin-1 and -2. J Biol Chem 279: 55419–55424.
Girnita L, Shenoy SK, Sehat B, Vasilcanu R, Vasilcanu D, Girnita A et al. (2007). Beta-arrestin and Mdm2 mediate IGF-1 receptor-stimulated ERK activation and cell cycle progression. J Biol Chem 282: 11329–11338.
Holaday JW, Berkowitz BA . (2009). Antiangiogenic drugs: insights into drug development from endostatin, avastin and thalidomide. Mol Interv 9: 157–166.
Kang J, Shi Y, Xiang B, Qu B, Su W, Zhu M et al. (2005). A nuclear function of beta-arrestin1 in GPCR signaling: regulation of histone acetylation and gene transcription. Cell 123: 833–847.
Kelly P, Moeller BJ, Juneja J, Booden MA, Der CJ, Daaka Y et al. (2006). The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci USA 103: 8173–8178.
Kohout TA, Lin FS, Perry SJ, Conner DA, Lefkowitz RJ . (2001). beta-Arrestin 1 and 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA 98: 1601–1606.
Kvietikova I, Wenger RH, Marti HH, Gassmann M . (1995). The transcription factors ATF-1 and CREB-1 bind constitutively to the hypoxia-inducible factor-1 (HIF-1) DNA recognition site. Nucleic Acids Res 23: 4542–4550.
Lakshmikanthan V, Zou L, Kim JI, Michal A, Nie Z, Messias NC et al. (2009). Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer. Proc Natl Acad Sci USA 106: 9379–9384.
Lal A, Haynes SR, Gorospe M . (2005). Clean western blot signals from immunoprecipitated samples. Mol Cell Probes 19: 385–388.
Lefkowitz RJ, Rajagopal K, Whalen EJ . (2006). New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell 24: 643–652.
Lefkowitz RJ, Shenoy SK . (2005). Transduction of receptor signals by beta-arrestins. Science 308: 512–517.
Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V et al. (2006). Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6: 245.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N . (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306–1309.
Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM et al. (2009). Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7: 1064–1077.
Liu Y, Cox SR, Morita T, Kourembanas S . (1995). Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 77: 638–643.
Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P et al. (2003). Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA 100: 5974–5979.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271–275.
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature 436: 518–524.
Moeller BJ, Cao Y, Li CY, Dewhirst MW . (2004). Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5: 429–441.
Mythreye K, Blobe GC . (2009). The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 106: 8221–8226.
Niida A, Smith AD, Imoto S, Aburatani H, Zhang MQ, Akiyama T . (2009). Gene set-based module discovery in the breast cancer transcriptome. BMC Bioinformatics 10: 71.
Raghuwanshi SK, Nasser MW, Chen X, Strieter RM, Richardson RM . (2008). Depletion of beta-arrestin-2 promotes tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 180: 5699–5706.
Rosano L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A et al. (2009). Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106: 2806–2811.
Scott MG, Le Rouzic E, Perianin A, Pierotti V, Enslen H, Benichou S et al. (2002). Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem 277: 37693–37701.
Semenza GL . (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007: cm8.
Shenoy SK, Xiao K, Venkataramanan V, Snyder PM, Freedman NJ, Weissman AM . (2008). Nedd4 mediates agonist-dependent ubiquitination, lysosomal targeting, and degradation of the beta2-adrenergic receptor. J Biol Chem 283: 22166–22176.
Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M et al. (2005). Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. J Clin Oncol 23: 5334–5346.
Vlahovic G, Rabbani ZN, Herndon II JE, Dewhirst MW, Vujaskovic Z . (2006). Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 95: 1013–1019.
Wang GL, Jiang BH, Rue EA, Semenza GL . (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510–5514.
Wang GL, Semenza GL . (1995). Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230–1237.
Wang P, Wu Y, Ge X, Ma L, Pei G . (2003). Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem 278: 11648–11653.
Zou L, Yang R, Chai J, Pei G . (2008). Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis. FASEB J 22: 355–364.
Acknowledgements
We are grateful to Dr Lefkowitz for his insightful comments. We thank Ms Vidya Venkat for technical support. We acknowledge grant support from the NIH (HL080525 to SKS and CA40355 to MWD).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Shenoy, S., Han, S., Zhao, Y. et al. β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene 31, 282–292 (2012). https://doi.org/10.1038/onc.2011.238
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.238
Keywords
This article is cited by
-
YAP and endothelin-1 signaling: an emerging alliance in cancer
Journal of Experimental & Clinical Cancer Research (2021)
-
Nuclear βArrestin1 regulates androgen receptor function in castration resistant prostate cancer
Oncogene (2021)
-
β-arrestin 2 stimulates degradation of HIF-1α and modulates tumor progression of glioblastoma
Cell Death & Differentiation (2021)
-
β2-microglobulin has a different regulatory molecular mechanism between ER+ and ER− breast cancer with HER2−
BMC Cancer (2019)
-
β-arrestin1/YAP/mutant p53 complexes orchestrate the endothelin A receptor signaling in high-grade serous ovarian cancer
Nature Communications (2019)